According to market research, the Hypercoagulability Treatment industry will be worth US$ 670 million in 2023 and US$ 1,317.99 million by 2033, growing at a CAGR of 7% over the projected period. The market increased at a 4% CAGR between 2018 and 2022.
For In-depth insights, Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16682
The market’s expansion can be ascribed to increased awareness of hypercoagulability and its detrimental repercussions, as well as an increase in the prevalence of illnesses that raise the risk of hypercoagulability. As a result, there is a stronger need for treatment choices, which will almost certainly drive the development of new and novel treatments in the future. Furthermore, the market is expected to expand as hypercoagulability becomes more common and a greater emphasis is placed on improving patient treatment outcomes.
As a result of the industry’s promising development prospects, various startups are entering the market, such as Novela Neurotechnology, a US-based startup that has developed the Neureka AI-driven platform to accelerate drug discovery by decoding neurological activity in the brain.
Because of the region’s high prevalence of hypercoagulability, North America is predicted to have a considerable market share, accounting for about 40% of total market value throughout the projection period. Furthermore, government actions and research collaborations are promoting market expansion in North America. With an emphasis on point-of-care healthcare and an increase in the number of hospitals in India and China, the Asia Pacific industry is particularly positioned for expansion, creating a potential global market opportunity.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16682
Key Takeaways from the Market Study
- From 2018 to 2022, the Hypercoagulability Treatment market grew at a 4% CAGR.
- The global Hypercoagulability Treatment market is expected to grow at a 7% CAGR from 2023 to 2033.
- By 2033, the Hypercoagulability Treatment Market is expected to be worth US$ 1317.99 million.
- According to FMI study, hospitals have the largest market share.
- North America is expected to account for 40% of the market for Hypercoagulability Treatment.
- During the projected period, the Asia Pacific market is expected to grow rapidly, accounting for 20% of the total.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Hypercoagulability Treatment.” says an FMI analyst
Market Competition
Key players in the market include pharmaceutical companies such as Bristol-Myers Squibb, Pfizer, Sanofi, Johnson & Johnson and Roche along with the healthcare providers and technology companies among other global players.
- In May 2020, the US Food and Drug Administration (FDA) approved Qinlock (ripretinib) tablets as a fourth-line treatment option for advanced gastrointestinal stromal tumors (GIST). Qinlock is a kinase inhibitor and is indicated for patients who have received three or more prior kinase inhibitor treatments, including imatinib. The approval was based on results of a randomized, double-blind, placebo-controlled clinical trial that enrolled 129 patients with advanced GIST. The trial showed that progression-free survival (PFS) was longer in the group receiving Qinlock compared to the placebo group. Qinlock was administered once a day in 28-day cycles until disease progression or intolerable side effects. After disease progression, patients in the placebo group had the option to switch to Qinlock.
More Insights Available
North America dominates the hypercoagulability market due to the high prevalence of thrombophilia in the region, favorable reimbursement policies, and the presence of major market players. Europe is also a significant market for hypercoagulability, driven by the increasing awareness about the condition and the growing adoption of advanced diagnostic tests and personalized treatments.
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-16682
Key Segments Profiled in the Hypercoagulability Treatment Industry Survey
Drugs:
- Heparin
- Warfarin
- Direct Thrombin Inhibitor
Route of Administration:
- Oral
- Injectable
End Users:
- Hospitals
- Speciality Centers
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs